Skip to main content
Journal cover image

Results of thoracic endovascular aortic repair 6 years after United States Food and Drug Administration approval.

Publication ,  Journal Article
Shah, AA; Barfield, ME; Andersen, ND; Williams, JB; Shah, JA; Hanna, JM; McCann, RL; Hughes, GC
Published in: Ann Thorac Surg
November 2012

BACKGROUND: Since United States Food and Drug Administration approval in 2005, the short-term safety and efficacy of thoracic endovascular aortic repair (TEVAR) have been established. However, longer-term follow-up data remain lacking. The objective of this study is to report 6-year outcomes of TEVAR in clinical practice. METHODS: A prospective cohort review was performed of all patients undergoing TEVAR at a single referral institution between March 2005 and May 2011. Rates of reintervention were noted. Overall and aortic-specific survival were determined using Kaplan-Meier methods. Log-rank tests were used to compare survival between groups. RESULTS: During the study interval, 332 TEVAR procedures were performed in 297 patients. Reintervention was required after 12% of procedures at a mean of 8 ± 14 months after initial TEVAR and was higher in the initial tercile of patients (15.0% vs 9.9%). The 6-year freedom from reintervention was 84%. Type I endoleak was the most common cause of reintervention (5%). Six-year overall survival was 54%, and aorta-specific survival was 92%. Long-term survival was significantly lower than that of an age- and sex-matched United States population (p < 0.001). Survival was similar between patients requiring a reintervention vs those not (p = 0.26). Survival was different based on indication for TEVAR (p = 0.007), and patients with degenerative aneurysms had the lowest survival (47% at 6 years). Cardiopulmonary pathologies were the most common cause of death (27 of 93 total deaths). CONCLUSIONS: Long-term aortic-related survival after TEVAR is high, and the need for reintervention is infrequent. However, overall long-term survival is low, particularly for patients with degenerative aneurysms, and additional work is needed to identify patients unlikely to derive a survival benefit from TEVAR.

Duke Scholars

Published In

Ann Thorac Surg

DOI

EISSN

1552-6259

Publication Date

November 2012

Volume

94

Issue

5

Start / End Page

1394 / 1399

Location

Netherlands

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Treatment Outcome
  • Time Factors
  • Survival Rate
  • Respiratory System
  • Reoperation
  • Prospective Studies
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shah, A. A., Barfield, M. E., Andersen, N. D., Williams, J. B., Shah, J. A., Hanna, J. M., … Hughes, G. C. (2012). Results of thoracic endovascular aortic repair 6 years after United States Food and Drug Administration approval. Ann Thorac Surg, 94(5), 1394–1399. https://doi.org/10.1016/j.athoracsur.2012.05.072
Shah, Asad A., Michael E. Barfield, Nicholas D. Andersen, Judson B. Williams, Julie A. Shah, Jennifer M. Hanna, Richard L. McCann, and G Chad Hughes. “Results of thoracic endovascular aortic repair 6 years after United States Food and Drug Administration approval.Ann Thorac Surg 94, no. 5 (November 2012): 1394–99. https://doi.org/10.1016/j.athoracsur.2012.05.072.
Shah AA, Barfield ME, Andersen ND, Williams JB, Shah JA, Hanna JM, et al. Results of thoracic endovascular aortic repair 6 years after United States Food and Drug Administration approval. Ann Thorac Surg. 2012 Nov;94(5):1394–9.
Shah, Asad A., et al. “Results of thoracic endovascular aortic repair 6 years after United States Food and Drug Administration approval.Ann Thorac Surg, vol. 94, no. 5, Nov. 2012, pp. 1394–99. Pubmed, doi:10.1016/j.athoracsur.2012.05.072.
Shah AA, Barfield ME, Andersen ND, Williams JB, Shah JA, Hanna JM, McCann RL, Hughes GC. Results of thoracic endovascular aortic repair 6 years after United States Food and Drug Administration approval. Ann Thorac Surg. 2012 Nov;94(5):1394–1399.
Journal cover image

Published In

Ann Thorac Surg

DOI

EISSN

1552-6259

Publication Date

November 2012

Volume

94

Issue

5

Start / End Page

1394 / 1399

Location

Netherlands

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Treatment Outcome
  • Time Factors
  • Survival Rate
  • Respiratory System
  • Reoperation
  • Prospective Studies
  • Middle Aged
  • Male